Interleukin 3, Recombinant, Rat (IL-3)

Cat# I7663-36R-2ug

Size : 2ug

Brand : US Biological

Contact local distributor :


Phone : +1 850 650 7790


I7663-36R Rabbit Anti-Interleukin 3, Recombinant, Rat (IL-3) discontinued

Clone Type
Polyclonal
Grade
Highly Purified
Shipping Temp
Blue Ice
Storage Temp
-20°C

Interleukin-3 (IL-3) is a cytokine produced by activated T-cells and mast cells that is active on a broad range of hematopoietic cells and in the nervous system and appears to be important in several chronic inflammatory diseases||Description: |Recombinant Rat IL-3 produced in E.Coli is a single, non-glycosylated polypeptide chain containing 140 amino acids and having a molecular mass of 15783 Dalton. Recombinant Rat IL-3 is purified by proprietary chromatographic techniques.||Amino Acid Sequence: |The sequence of the first five N-terminal amino acids was determined and was found to be Met-Ser-Asp-Arg-Gly.||Dimers and Aggregates: |Less than 1% as determined by silver-stained SDS-PAGE gel analysis.||Biological Activity: |rrIL-3 is fully biologically active when compared to standard. The ED50 as determined by the dose-dependent stimulation of thymidine uptake by murine MC-9 cells is < 0.05 ng/ml, corresponding to a Specific Activity of 1 x 10e5 IU/mg.||Endotoxin: |≤ 0.1ng/ug (IEU/ug) of Recombinant Rat IL-3.||Protein Content: |Protein quantitation was carried out by two independent methods:|1. UV spectroscopy at 280 nm using the absorbency value of 0.171 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). |2. Analysis by RP-HPLC, using a standard solution of Rat IL-3 as a Reference Standard.||Gene: |Name: Il3; Synonyms: Il-3||Solubility: |It is recommended to reconstitute the lyophilized IL-3 in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.||Stability: |Lyophilized Rat IL-3 although stable at room temperature for 3 weeks, should be stored desiccated below -180C. Upon reconstitution Interleukin-3 should be stored at 40C between 2-7 days and for future use below -180C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

Applications
Source: Recombinant, E. coli|Purity: ≥ 98% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.|Concentration: ~1mg/ml|Form: Supplied as a lyophilized powder in 5mM sodium citrate, pH 4.0.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as a lyophilized powder in 5mM sodium citrate, pH 4.0.
Purity
≥ 98% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.
References
1. Cell cycle kinetic changes induced by interleukin-3 and interleukin-6 during ex vivo expansion of mobilized peripheral blood CD34 cells.||Haematologica 2006 Jan;91(1):121-4||2. Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients.||Blood 2006 Jan 15;107(2):841-2||3. Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.||J Biol Chem 2006 Mar 3;281(9):5426-34||4. Interleukin-3, -5, and granulocyte macrophage colony-stimulating factor induce adhesion and chemotaxis of human eosinophils via p38 mitogen-activated protein kinase and nuclear factor kappaB.||Immunopharmacol Immunotoxicol 2005;27(3):371-93||5. S6 kinase 2 potentiates interleukin-3-driven cell proliferation.||J Leukoc Biol 2005 Dec;78(6):1378-85||6. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.||Leukemia 2005 Nov;19(11):1929-33